BEGIN:VCALENDAR VERSION:2.0 PRODID:-//CURE GABA-A - ECPv6.15.20//NONSGML v1.0//EN CALSCALE:GREGORIAN METHOD:PUBLISH X-ORIGINAL-URL:https://curegabaa.org X-WR-CALDESC:Events for CURE GABA-A REFRESH-INTERVAL;VALUE=DURATION:PT1H X-Robots-Tag:noindex X-PUBLISHED-TTL:PT1H BEGIN:VTIMEZONE TZID:America/Los_Angeles BEGIN:DAYLIGHT TZOFFSETFROM:-0800 TZOFFSETTO:-0700 TZNAME:PDT DTSTART:20230312T100000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0700 TZOFFSETTO:-0800 TZNAME:PST DTSTART:20231105T090000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0800 TZOFFSETTO:-0700 TZNAME:PDT DTSTART:20240310T100000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0700 TZOFFSETTO:-0800 TZNAME:PST DTSTART:20241103T090000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0800 TZOFFSETTO:-0700 TZNAME:PDT DTSTART:20250309T100000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0700 TZOFFSETTO:-0800 TZNAME:PST DTSTART:20251102T090000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0800 TZOFFSETTO:-0700 TZNAME:PDT DTSTART:20260308T100000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0700 TZOFFSETTO:-0800 TZNAME:PST DTSTART:20261101T090000 END:STANDARD END:VTIMEZONE BEGIN:VTIMEZONE TZID:Asia/Krasnoyarsk BEGIN:STANDARD TZOFFSETFROM:+0700 TZOFFSETTO:+0700 TZNAME:+07 DTSTART:20250101T000000 END:STANDARD END:VTIMEZONE BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20240528T110000 DTEND;TZID=America/Los_Angeles:20240528T120000 DTSTAMP:20260419T085258 CREATED:20240526T073155Z LAST-MODIFIED:20240528T072840Z UID:2994-1716894000-1716897600@curegabaa.org SUMMARY:Cure GABA-A | What do we need to know about Gain of Function GABAAR DESCRIPTION:What do we need to know about Gain of Function GABAA receptor variants?\n\n\nUnderstanding Gain of Function GABAA Receptor Variants\nGABAA Receptor Variants | Research Insights Session | Dr. Lidong Liu \nJoin us for an enlightening session with Dr. Lidong Liu\, Senior Research Scientist at the University of British Columbia’s Department of Neurology and the DM Centre for Brain Health. \nDr. Liu\, in collaboration with Dr. Yu Tian Wang\, focuses on the molecular mechanisms of synaptic function and plasticity\, particularly under conditions of health and disease. This session will describe GABAA receptor variants and their implications for epilepsy. \nThese groundbreaking insights are crucial for developing better treatments for conditions like epilepsy. Dr. Liu’s work highlights the dynamic interplay between neurotransmitter systems and offers new avenues for therapeutic intervention. \nEvent Details: \n\nDate: 5/28/2024\nTime: 11am PDT\n\nIf you cannot attend in person\, don’t worry—the session will be recorded and available on our YouTube channel. \nJoin us to learn from Dr. Liu’s expertise and contribute to our shared mission of improving the lives of patients with GABAA receptor variants. \nProject Overview: \n\nGABAA Receptor Study: This project focuses on understanding GABAA receptors.\nInitial Discovery: The first GABRA1 variant (A322D) was identified in epilepsy patients about 20 years ago.\nRecent Work: Recently\, more variants have been characterized\, and some repurposed drugs have been tested on these variants based on requests from doctors and patients’ families.\n\nKey Discoveries: \n\nGlutamate and GABAA Receptor Crosstalk:\nSignificance: There is an important interaction between glutamate and GABAA receptors.\nMechanism: Glutamate can bind to and enhance GABAA receptors to balance out the overexcitation caused by glutamate receptors.\nResearch Model: Mice with mutations in the glutamate binding site of GABAA receptors showed increased neuronal excitability\, seizure susceptibility\, and autism-like behaviors.\nNetrin-1’s Role:\nFunction: Netrin-1\, a molecule that guides axons\, is secreted during high neuronal activity.\nEffect: It binds to GABAA receptors and increases their function\, helping to balance synaptic activity by enhancing the conductance of these channels. URL:https://curegabaa.org/event/cure-gaba-a-what-do-we-need-to-know-about-gain-of-function-gabaar/ ATTACH;FMTTYPE=image/jpeg:https://curegabaa.org/wp-content/uploads/2024/05/f1d24b9620acb6390d5f7155e6ff2514-1.jpg ORGANIZER;CN="CURE GABA-A":MAILTO:info@curegabaa.org END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20240529T100000 DTEND;TZID=America/Los_Angeles:20240529T110000 DTSTAMP:20260419T085258 CREATED:20240526T073209Z LAST-MODIFIED:20240528T072840Z UID:2998-1716976800-1716980400@curegabaa.org SUMMARY:Cure GABA-A | Dr. Ortiz Community Update Meeting DESCRIPTION:We invite you to a special presentation that will NOT be recorded. Dr. Ortiz will discuss three key points for our community.\n\n\nWe invite you to a special presentation that will NOT be recorded. Dr. Ortiz will discuss three key points at our upcoming Cure GABA-A meeting for patients and caregivers: \n \n1. The preliminary results of the antiseizure medication survey completed by our community. \n(https://filadelfia-science.dk/surveys/?s=TEX9JXNK3CPWTNA4) \n \n2. An explanation of the Sleep Disturbance Scale for our children. \n \n3. The GABAAR Movement Disorders clinical video proposal featuring the MyDystonia electronic diary. \n \nWe hope to see you all there. URL:https://curegabaa.org/event/cure-gaba-a-dr-ortiz-community-update-meeting/ ATTACH;FMTTYPE=image/jpeg:https://curegabaa.org/wp-content/uploads/2024/05/e678b4aa2c9d7883d74f72279b0f50a1-1.jpg ORGANIZER;CN="CURE GABA-A":MAILTO:info@curegabaa.org END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20240627T130000 DTEND;TZID=America/Los_Angeles:20240627T140000 DTSTAMP:20260419T085258 CREATED:20240626T183301Z LAST-MODIFIED:20240627T184424Z UID:3092-1719493200-1719496800@curegabaa.org SUMMARY:Cure GABA-A | Artificial Intelligence (AI)-driven Drug Repurposing for Rare DESCRIPTION:Aleksandra Foksinska\, Program Manager\, and Alexandria Howard\, Case Analyst at UAB Hugh Kaul Precision Medicine Institute\, research AI-driven\n\n\nAleksandra Foksinska and Alexandria Howard will both discuss Artificial Intelligence (AI)-driven Drug Repurposing for Rare Disease. \nAleksandra Foksinska is the Program Manager at the UAB Hugh Kaul Precision Medicine Institute. Her background is in Molecular Biology (BS) and Biomedical Sciences (MS) from the University of Alabama at Birmingham. Aleksandra’s research interests include identifying drug repurposing candidates for rare genetic disorders using AI. Aleksandra also serves as a project coordinator for the UAB Center for Precision Animal Modeling\, as well as a committee member for the Undiagnosed Diseases Network Therapeutic Matching Committee. \nAlexandria Howard is a Case Analyst at the UAB Hugh Kaul Precision Medicine Institute. She is currently approaching her senior year at the University of Alabama at Birmingham with a double major in Genetics/Genomic Sciences and Neuroscience and a minor in Chemistry. Alexandria’s research interests include investigating various rare genetic disorders and identifying drug repurposing candidates using AI. URL:https://curegabaa.org/event/cure-gaba-a-artificial-intelligence-ai-driven-drug-repurposing-for-rare/ ATTACH;FMTTYPE=image/jpeg:https://curegabaa.org/wp-content/uploads/2024/06/71125d09bbf5aa52e477b4e421030c69-1.jpg ORGANIZER;CN="CURE GABA-A":MAILTO:info@curegabaa.org END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20240628T100000 DTEND;TZID=America/Los_Angeles:20240628T110000 DTSTAMP:20260419T085258 CREATED:20240626T183309Z LAST-MODIFIED:20240627T184424Z UID:3096-1719568800-1719572400@curegabaa.org SUMMARY:Cure GABA-A | Genotype-phenotype correlation&precision treatment of epilesy DESCRIPTION:The research focuses on genetic epilepsy\, aiming to identify severe epilepsy genotypes and develop precision therapies.\n\n\nThe current landscape shows increasing insights into human genetics\, yet the translation of genetic data into actionable patient care concepts lags behind. This gap is influenced by two primary challenges: the variability in clinical outcomes associated with different genetic variants within a single gene\, complicating treatment decisions\, and the empirical nature of current epilepsy treatments due to the absence of targeted therapies for specific genetic changes. \nOur specific focus is on the genetic LOF variant D120N in the GABRB3 gene’s beta-3 subunit\, known for severe forms of developmental and epileptic encephalopathy (DEE)\, such as Lennox Gastaut Syndrome (LGS). This variant’s location in the gene’s extracellular region suggests a correlation with clinical severity based on functional domains. However\, understanding which genetic variants correlate with mild or severe presentations remains a challenge\, impacting prognostication and treatment strategies. Furthermore\, the pathophysiology and underlying cellular mechanisms associated with these genetic variants require further investigation. \nThrough this research\, I aim to contribute to the advancement of personalized medicine\, ultimately improving outcomes for children affected by genetic epilepsy. URL:https://curegabaa.org/event/cure-gaba-a-genotype-phenotype-correlationprecision-treatment-of-epilesy/ ATTACH;FMTTYPE=image/jpeg:https://curegabaa.org/wp-content/uploads/2024/06/0a00c3597b9dc28dc63fee28a583eac9-1.jpg ORGANIZER;CN="CURE GABA-A":MAILTO:info@curegabaa.org END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20250926T130000 DTEND;TZID=America/Los_Angeles:20250926T143000 DTSTAMP:20260419T085258 CREATED:20250923T065822Z LAST-MODIFIED:20250926T071539Z UID:4354-1758891600-1758897000@curegabaa.org SUMMARY:CURE GABA-A | Grann Pharmaceuticals mRNA Protein Replacement for GABAARs DESCRIPTION:First glimpse at mRNA protein replacement for GABAAR disorders. Join CURE GABA-A + Grann Pharma live Q&A this Friday at 1PM PST.\n\n\nCURE GABA-A | Grann Pharmaceuticals: mRNA Protein Replacement for GABAAR Disorders \n \nDate & Time\n📅 Friday\, September 26th 2025🕐 1:00 PM PST | 4:00 PM EST \nLocation\nOnline Event (Zoom link provided upon registration) \nDescription\n🚨 STOP WHAT YOU’RE DOING 🚨 \nThis is the moment everything we’ve worked for comes down to. We started CURE GABA-A with one mission: to get pre clinical data for treatments relating to GABAAR disorders as quickly and safely as possible. And now\, we are finally at the beginning. \nGrann Pharmaceuticals has developed an mRNA-based protein replacement therapy for GABRA1 and GABRG2 variants. This therapy is already produced and ready for preclinical testing. With the right support\, we can bring it to the FDA and into clinical trials by the end of 2026. \nBut science alone isn’t enough. We need the community to band together now\, fundraising\, donating\, and spreading the word\, to make this therapy a reality for children and families. \nJoin us for a live Q&A with Tommy Temple\, CEO of Grann Pharmaceuticals\, as he explains: \n\nWhat mRNA protein replacement therapy is\nWhy it could be the first treatment for GABAAR disorders\nThe FDA pathway and clinical trial timeline\nHow YOU can make the difference to bring this to clinic\n\n💙 Together we can move from hope to treatment. \n \nAgenda\n\nWelcome from CURE GABA-A\nPresentation by Tommy Temple (CEO\, Grann Pharmaceuticals)\nLive Q&A session\nCall to Action: How to Fundraise and Donate\n\n \nTickets\n🎟️ Free – Registration required.Donations encouraged: https://www.facebook.com/donate/4300256346872932/ \nor GoFundMe: https://www.gofundme.com/f/lifesaving-gene-therapy-drug \n \nCall to Action\n✨ Every donation moves us closer to the first-ever GABAAR clinical trial.✨ Every fundraiser brings hope to families waiting for answers. \n👉 Register now\, join the movement\, and help us make history. URL:https://curegabaa.org/event/cure-gaba-a-grann-pharmaceuticals-mrna-protein-replacement-for-gabaars/ ATTACH;FMTTYPE=image/jpeg:https://curegabaa.org/wp-content/uploads/2025/09/eb129fe2f5040dd1250b287baff34beb.jpg ORGANIZER;CN="CURE GABA-A":MAILTO:info@curegabaa.org END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20261203 DTEND;VALUE=DATE:20261205 DTSTAMP:20260419T085258 CREATED:20251210T173503Z LAST-MODIFIED:20260121T213743Z UID:4631-1796256000-1796428799@curegabaa.org SUMMARY:2026 CURE GABA-A Family & Scientific Conference DESCRIPTION:2026\nCURE GABA-A Family & Scientific \nConference\n \n \n \n \n \n December 3rd -4th 2026\, Denver Colorado USA \n \n Register to Attend\n \n Sponsor the Conference\n \n \n \n \n \n Two days of scientific presentations\, family programming\, GABA-A Receptor research updates\, and global collaboration. \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n 2023 Roundtable\n \n \n \n \n \n \n \n 2024 Conference\n \n \n \n \n \n \n \n 2025 European Conference\n \n \n \n \n \n \n \n 2025 Conference\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Countdown\n \n \n Day(s) \n \n : \n \n \n Hour(s) \n \n : \n \n \n Minute(s) \n \n : \n \n \n Second(s) \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n   \nWhat\, When and Where\n\n\n\n\n\n\n\n\n\n\n\nWhat:\n2026 CURE GABA-A Family & Scientific Conference \n \nWhen:\n\n\n\n\nFamily Meeting | December 2nd\, 2026 \nScientific Meeting | December 3rd\, 2026 \nWhere:\nDenver\, Colorado – Hotel Details to be confirmed by Q2 of 2026 \n\n\n\n\n\n\n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Featured Talks & Speakers\n \n Full Schedule Available soon\n \n \n \n \n \n \n \n \n \n \n \n \nWhat to Expect\nDiscover the leading voices shaping the future of GABAAR research. \nOur 2026 conference features presentations from global experts in GABAAR science\, neuroscience\, clinical care\, gene therapy\, and translational research. \nAttendees will hear the latest updates on GABAAR science\, therapeutic development\, natural history studies\, iPSC research\, animal models\, and real-world clinical insights. \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Rikke S Møller\nProfessor\, Coordinative Head of Research\, IRS \nThe Epilepsy hospital Filadelfia \nNatural History and EEG Biomarkers \n \n More Details\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Jingqiong Kang (Katty)\nAssociate Professor of Neurology and Pharmacology \nVanderbilt University Medical Center \nRavicti Repurposing \n \n More Details\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Henry Lee\nPreclinical Scientific Program Manager \nHarvard Medical School \nGene Replacement Therapy \n \n More Details\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Thomas Lyle Temple\nCEO\, Grann Pharmaceuticals  \nmRNA Therapy \n \n  \n \n More Details\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n SCIENTIFIC PROGRAM\n \n \n \n \n \n \n \n FAMILY PROGRAM\n \n \n \n \n \n \n \n BIO SAMPLE COLLECTION\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n 2026 Conference Highlights\n\nUpdated GABAAR research\nmRNA protein replacement therapy progress\nGene Replacement Therapy progress\nMouse model and zebrafish updates\nOn-site bio sample collection through COMBINEDBrain\nParent and caregiver workshops\nGlobal scientific and advocacy speakers\nOpportunities to network with researchers\nDedicated respite room and support resources\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Venue\n Our venue will be announced soon. We are finalizing a location that provides: \n\nSpacious meeting rooms\nComfortable accommodations\nFamily-friendly dining options\nAccessibility features\nEasy access to Denver International Airport (DEN)\n\nFull venue details and the hotel room block will be added here as soon as they are confirmed. \nHotel Room Block\nWe will be offering a discounted room block for attendees.Room block details\, including booking links and deadline dates\, will be released once the venue contract is finalized. \nWe encourage you to check this page regularly or join our email list for updates. \nTravel Planning\nTo help families manage costs\, we encourage booking airfare as early as February. Flights to Denver tend to increase in price as summer approaches\, so early planning can make a big difference. \n \n \n \n \n \n On-Site Bio sample Collection\n \n\n\n\n\nAt the 2026 CURE GABA-A Conference\, families will have the opportunity to take part in on-site bio sample collection through COMBINEDBrain\, our national research and bio collection partner. \n \nWho Can Participate\nFamilies of individuals with confirmed or suspected GABAAR variants are welcome to take part. Samples may include saliva\, blood\, or other non-invasive collections depending on the research protocol.\n \nWhy It Matters\nEvery sample helps researchers better understand GABAAR variants and how they affect development\, seizures\, expression\, and brain function. These samples accelerate the development of new treatments\, including mRNA therapy\, protein replacement\, drug screening\, and biomarker discovery.\nYour contribution moves research forward in a tangible\, measurable way.\n \nWhat COMBINEDBrain Does\nCOMBINEDBrain is a leading research consortium focused on severe neurodevelopmental disorders. They work with top scientists and hospitals to process\, store\, and analyze biosamples so data can be used responsibly and effectively across multiple research programs. Their work ensures that every sample contributes to real progress.\n \nHow to Sign Up\nWe will release a sign-up link closer to the event. Families will be able to select a time slot that works best for their schedule.\nSpaces may be limited\, so we encourage early registration once sign-ups open.\n\n\n\n\n\n\n \n \n Bio Collection Registry\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n For Families\n Learn the latest science in a supportive environment \nConnect with families from around the world \nAccess resources and variant-specific insights \nParticipate in biosample programs that accelerate research \nMeet the scientists who are actively working on GABAAR therapeutics \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Researchers & Clinicians\n Present your work to a global\, engaged audience \nAccess a rare and concentrated dataset across GABA-A receptor variants \nEngage directly with families and community leaders \nCollaborate with global labs \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n For Sponsors\n Align with high-impact rare disease research \nGain visibility among families\, scientists\, and clinicians \nSupport the advancement of GABAAR  therapeutics \nReinforce your corporate commitment to neurological innovation \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Our Sponsors\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Thanking our previous years sponsors\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Register Now!\n \n \n \n \n \n Lorem ipsum dolor sit amet\, consectetur adipiscing elit. Quisque placerat sapien condimentum imperdiet cursus. Lorem ipsum dolor sit amet\, consectetur adipiscing elit. Quisque placerat sapien condimentum imperdiet cursus.\n \n Ticket Info\n \n \n \n \n \n \n \n \n \n \n \n \n Contact Us\n \n \n \n \n \n \n \n \n \n Name\n \n \n \n \n \n \n Email\n \n \n \n \n \n \n Message\n \n \n \n \n \n Submit\n \n \n \n \n \n \n \n \n \n \n Have questions? We’re here to help.Email: info@curegabaa.org  \n30765 Pacific Coast Hwy Suite 366 Malibu\, CA 90265 United States \nEIN: 93-1989277 URL:https://curegabaa.org/event/2026conference/ CATEGORIES:CURE GABA-A Conferences ORGANIZER;CN="CURE GABA-A":MAILTO:info@curegabaa.org END:VEVENT END:VCALENDAR